About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
C4 Therapeutics is seeking a highly motivated Quantitative Systems Pharmacology Modeler/ DMPK Project Team Representative to contribute to the discovery and development of small molecule therapeutics that enable the UPS-mediated degradation of proteins implicated in disease. Reporting to the Director of DMPK, the ideal candidate will be responsible for developing QSP/PBPK models for C4T’s pipeline, representing DMPK function on project teams, problem solving, and ongoing nimble integration of the discipline into C4T’s advancing portfolio.
- In this role, the individual will work with integrated project teams to co-develop medicinal chemistry strategy and DMPK screening strategy to address in vivo performance issues, through analysis based on QSP/PBPK based models, in vitro ADME and PK.
- Selecting and balancing internal data production with external CRO capabilities to ensure high quality and on-time execution of ADME studies.
- Responsible for bridging the in-vitro cell pharmacology data and in-vivo PK/PD observations to develop robust and predictive QSP/PBPK models
- Design, management, analysis and interpretation of ADME, PK and PK/PD studies
- The candidate will be required to analyze and present data and trends, both orally and as written reports.
- A Ph.D. in pharmaceutical or related discipline with ≥ 3 year industry experience or a BS/MS in pharmaceutical sciences, analytical chemistry or related disciplines with ≥ 7 years of industry experience in a DMPK/Pharmacometrics setting.
- Demonstrable expertise and experience in developing QSP models
- Extensive knowledge of in-vitro/in-vivo ADME properties for small molecules.
- Experience working as DMPK representative on drug discovery programs is desirable